Chief Scientific Officer
cardiac stem cell
AC Immune
Switzerland
Prior to joining AC Immune, Dr. Muhs was responsible the development of the cardiac stem cell-based program to treat myocardial infarct patients, including worldwide pre-clinical program collaborations and technology transfers at ViaCell Inc., Cambridge, MA, for. Prior to ViaCell Inc. he held the position of Director of Pharmacology & Histology at Cardion AG where he developed research projects to clinical approaches in the fields of heart & circulation, angiogenesis, immunology, diabetes and toxicology with gene-, protein- and stem cell-based therapies. Dr. Muhs holds a PhD in Biology from the University Düsseldorf, Germany, where he worked on regulation of endothelial barrier functions.
heart & circulation, angiogenesis, immunology, diabetes and toxicology